These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1884730)

  • 21. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.
    Kalow W; Otton SV; Kadar D; Endrenyi L; Inaba T
    Can J Physiol Pharmacol; 1980 Sep; 58(9):1142-4. PubMed ID: 7459706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Debrisoquine hydroxylation in a Polish population.
    Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
    Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population.
    Wanwimolruk S; Pratt EL; Denton JR; Chalcroft SC; Barron PA; Broughton JR
    Pharmacogenetics; 1995 Aug; 5(4):193-8. PubMed ID: 8528265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
    Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
    Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.
    al-Hadidi HF; Irshaid YM; Rawashdeh NM
    Eur J Clin Pharmacol; 1994; 47(4):311-4. PubMed ID: 7875180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.
    Xu XM; Jiang WD
    Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):385-8. PubMed ID: 2130590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.
    Spina E; Campo GM; Calandra S; Caputi AP; Carrillo JA; Benitez J
    Pharmacol Res; 1992 Jan; 25(1):43-50. PubMed ID: 1738757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
    Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic cytochrome P450-mediated oxidation function in migraine.
    Amery WK; Davies PT; Caers LI; Heykants J; Steiner TJ; Woestenborghs R; Rose FC
    Cephalalgia; 1988 Jun; 8(2):71-4. PubMed ID: 3401919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphic 2-hydroxylation of desipramine. A population and family study.
    Dahl ML; Iselius L; Alm C; Svensson JO; Lee D; Johansson I; Ingelman-Sundberg M; Sjöqvist F
    Eur J Clin Pharmacol; 1993; 44(5):445-50. PubMed ID: 8359181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphic 4-hydroxylation of debrisoquine in a Turkish population.
    Sardas S; Pontin J; Idle JR
    Pharmacogenetics; 1991 Nov; 1(2):123-4. PubMed ID: 1844871
    [No Abstract]   [Full Text] [Related]  

  • 38. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.